1. Signaling Pathways
  2. Neuronal Signaling
  3. Beta-secretase

Beta-secretase

BACE; β-Secretase

Beta-secretase (BACE) is a transmembrane aspartic proteinase responsible for cleaving the amyloid precursor protein (APP) to generate the soluble ectodomain sAPPbeta and its C-terminal fragment CTFbeta. BACE is a major target of Alzheimer's disease (AD) therapeutics. There are two forms of the enzyme: BACE1 and BACE2.

Deposition of amyloid-β protein (Aβ) to form neuritic plaques is the characteristic neuropathology of Alzheimer's disease (AD). Aβ is generated from APP by β- and γ-secretase cleavages. BACE1 is the β-secretase and its inhibition induces severe side effects, whereas its homolog BACE2 normally suppresses Aβ by cleaving APP/Aβ at the θ-site (Phe20) within the Aβ domain.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-RS01338
    Bace2 Rat Pre-designed siRNA Set A
    Inhibitor

    Bace2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Bace2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Bace2 Rat Pre-designed siRNA Set A
    Bace2 Rat Pre-designed siRNA Set A
  • HY-P4919
    Mca-SEVNLDAEFK(Dnp)
    Mca-SEVNLDAEFK(Dnp) is a Beta-secretase 1 (BACE-1) peptide FRET substrate, containing the 'Swedish' Lys-Met/Asn-Leu mutation of the amyloid precursor protein (APP) β-secretase cleavage site. Cleavage at -Leu-Asp- of Mca-SEVNLDAEFK(Dnp) liberates the highly fluorescent 7-methoxycoumarin (Mca) fragment from the proximity quenching effect of the 2,4-dinitrophenyl (Dnp) internal quencher resulting in a large and easily detectable increase in fluorescence intensity.
    Mca-SEVNLDAEFK(Dnp)
  • HY-P10077
    GL189
    Inhibitor
    GL189 is a β-secretase inhibitor. GL189 has neuroprotective effect, and can be used for research of neurodegenerative diseases.
    GL189
  • HY-153255
    BACE1-IN-13
    Inhibitor
    BACE1-IN-13 (Compound 36) is an orally active BACE1 inhibitor with an IC50 value of 2.9 nM. BACE1-IN-13 is highly potent in hAβ42 cell (IC50 = 1.3 nM). BACE1-IN-13 has cardiovascularly safty and elicits sustained Aβ42 reduction in mouse and dog animal models.
    BACE1-IN-13
  • HY-114245B
    Se-Methylselenocysteine hydrochloride
    Inhibitor
    Se-Methylselenocysteine hydrochloride, a precursor of Methylselenol, has potent cancer chemopreventive activity and anti-oxidant activity. Se-Methylselenocysteine hydrochloride is orally bioavailable, and induces apoptosis.
    Se-Methylselenocysteine hydrochloride
  • HY-147659
    AChE/BChE/BACE-1-IN-2
    Inhibitor
    AChE/BChE/BACE-1-IN-2 (Compound 4o) is an orally active inhibitor of AChE, BChE, and BACE-1 with IC50 values of 0.069, 0.127 and 0.097 μM against hAChE, hBChE and hBACE-1, respectively. AChE/BChE/BACE-1-IN-2 shows considerable PAS-AChE binding capability, excellent brain permeation, potential disassembly of Aβ aggregates, and neuroprotective activity against Aβ-induced stress. AChE/BChE/BACE-1-IN-2 has remarkable antioxidant potential.
    AChE/BChE/BACE-1-IN-2
  • HY-161359
    BACE1-IN-14
    Inhibitor
    BACE1-IN-14 (compound 27f) is a BACE1 inhibitor, with the EC50 values of 0.7 μM and 1.6 μM for BACE1 and BACE2. BACE1-IN-14 is can be used in Alzheimer's disease (AD) research.
    BACE1-IN-14
  • HY-147870
    COX-2-IN-22
    Inhibitor
    COX-2-IN-22 (Compound 4h) is a COX-2 inhibitor with an IC50 of 8.6 µM. COX-2-IN-22 also inhibits AChE, BChE, β-Secretase, LOX-5 and DPPH with IC50 values of 2.8, 6.3, 15.3, 13.9 and 6.8 µM, respectively. COX-2-IN-22 can cross BBB.
    COX-2-IN-22
  • HY-144739
    BACE1-IN-8
    Inhibitor
    BACE1-IN-8 (compound 70b) is a potent BACE1 (β-site APP cleaving enzyme 1) inhibitor, with an IC50 of 3.9 µM.
    BACE1-IN-8
  • HY-136813
    Multitarget AD inhibitor-1
    Inhibitor
    Multitarget AD inhibitor-1 is a selective and reversible butyrylcholinesterase (BuChE) inhibitor with IC50s of 7.22 μM and 1.55 μM for hBuChE and eqBuChE (BuChE from equine serum), respectively. Multitarget AD inhibitor-1 inhibits β-secretase (IC50hBACE-1=41.60 μM), amyloid β aggregation (IC50Aβ=3.09 μM), tau aggregation. Multitarget AD inhibitor-1, a diphenylpropylamine derivative, has the potential for multifunctional disease-modifying anti-Alzheimer’s research.
    Multitarget AD inhibitor-1
  • HY-159151
    AChE/Aβ-IN-6
    Inhibitor
    BACE1-IN-15 (compound 4j) is a potent inhibitor of BACE1 (β-secretase) that can inhibited the copper ion induced Aβ toxicity, with the EC50 of 0.68 μM.
    AChE/Aβ-IN-6
  • HY-151348
    BACE1-IN-11
    Inhibitor
    BACE1-IN-11 is a BACE1 inhibitor. BACE1-IN-11 has the BACE1 inhibitory activity with an IC50 value of 72 μM. BACE1-IN-11 can be used for the research of Alzheimer’s disease (AD) .
    BACE1-IN-11
  • HY-RS01333
    BACE1 Human Pre-designed siRNA Set A
    Inhibitor

    BACE1 Human Pre-designed siRNA Set A contains three designed siRNAs for BACE1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    BACE1 Human Pre-designed siRNA Set A
    BACE1 Human Pre-designed siRNA Set A
  • HY-RS01336
    BACE2 Human Pre-designed siRNA Set A
    Inhibitor

    BACE2 Human Pre-designed siRNA Set A contains three designed siRNAs for BACE2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    BACE2 Human Pre-designed siRNA Set A
    BACE2 Human Pre-designed siRNA Set A
  • HY-B0703R
    Eslicarbazepine acetate (Standard)
    Inhibitor
    Eslicarbazepine acetate (Standard) is the analytical standard of Eslicarbazepine acetate. This product is intended for research and analytical applications. Eslicarbazepine acetate (BIA 2-093), an antiepileptic agent, is a dual a dual Inhibitor of β-Secretase and voltage-gated sodium channel.
    Eslicarbazepine acetate (Standard)
  • HY-158261
    AChE-IN-63
    Inhibitor
    AChE-IN-63 (Compound 5AD) is a selective inhibitor of hAChE (IC50=0.103 μM). AChE-IN-63 also inhibits hBChE and hBACE-1 (IC50= 10 μM (hBChE); 1.342 μM (hBACE-1)). AChE-IN-63 inhibits Aβ aggregation, preventing the formation and deposition of Aβ1-42. AChE-IN-63 can effectively penetrate the blood-brain barrier and is orally effective. It is primarily used in Alzheimer's disease research.
    AChE-IN-63
  • HY-147851
    BACE1-IN-12
    Inhibitor
    BACE1-IN-12 (compound 7g) is a potent and BBB-penetrated BACE1 inhibitor, with an IC50 of 8.9 µM. BACE1-IN-12 shows selective BuChE (butyrylcholinesterase) inhibitory activity with an IC50 of 3.2 µM. BACE1-IN-12 shows effective antioxidant effect with an IC50 of 10.2 μM (DPPH). BACE1-IN-12 might be served as a potential anti-Alzheimer agent.
    BACE1-IN-12
  • HY-139720
    β-Secretase Inhibitor III
    Inhibitor
    β-Secretase Inhibitor III is an extremely selective BACE1 inhibitor (Ki = 0.13 nM).
    β-Secretase Inhibitor III
  • HY-163885
    SSZ
    Inhibitor
    SSZ is a multi-target inhibitor, which targets multiple pathological mechanisms of Alzheimer's disease (AD). SSZ targets acetylcholinesterase, butyrylcholinesterase, β-site amyloid precursor protein cleavage enzyme 1 (BACE1), and γ-secretase. SSZ ameliorates Alzheimer’s diseases and exhibits neuroprotective effect in mice.
    SSZ
  • HY-RS01334
    Bace1 Mouse Pre-designed siRNA Set A
    Inhibitor

    Bace1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bace1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Bace1 Mouse Pre-designed siRNA Set A
    Bace1 Mouse Pre-designed siRNA Set A
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.